Once-monthly Boniva
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Initial results of Roche/GlaxoSmithKline's Phase III study of once-monthly Boniva (ibandronate) for the treatment of postmenopausal osteoporosis show monthly dosing at 100 mg and 150 mg was "at least equivalent to the 2.5 mg daily regimen in increasing lumbar spine bone mineral density" after one year of treatment. The MOBILE (Monthly Oral Ibandronate in Ladies) study is continuing for a second year. Once-daily Boniva was approved in May 2003; the firms have delayed launch until a less frequent dosing regimen is approved (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief). Merck's Fosamax (alendronate) and Procter & Gamble's Actonel (risedronate) are both dosed once weekly. Roche has projected Boniva will reach the market in 2005...
You may also be interested in...
Roche/GSK delay Boniva launch
Launch of Roche/GlaxoSmithKline's osteoporosis agent Boniva (formerly Bonviva) will await approval of a less frequent dosing regimen. Ibandronate was approved May 16 as a once-daily 2.5 mg tab. "for the treatment and prevention of osteoporosis in postmenopausal women." Roche says the "submission will be supplemented at the earliest possible opportunity, following the completion of ongoing Phase III clinical trials." Merck's Fosamax (alendronate) and Procter & Gamble's Actonel (risedronate) are both available as once-weekly regimens. Boniva approval was based on studies in women with postmenopausal osteoporosis demonstrating reductions in the incidence of new vertebral and non-vertebral fractures and improvement in bone mineral density...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.